Of 150 C-suite executives from pharmaceutical, biotechnology, and other life sciences companies surveyed by the Deloitte Center for Health Solutions across the U.S., Europe, and Asia, 75% said ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company committed ...

STOCKHOLM & RADNOR, Pa., December 30, 2024--(BUSINESS WIRE)--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc ...

STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)--$MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc ...

Ikena Oncology has announced a definitive merger agreement with Inmagene Biopharmaceuticals, focusing on the development of IMG-007, a non-depleting anti-OX40 monoclonal antibody aimed at treating ...

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The ...

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago focused on the development and commercialization of generic ...

India’s Intas has signed a deal to buy a UK generics business from Teva for £600 million, a sell-off required because of EU competition rules. Teva earlier this year bought the Actavis generics ...